Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study

Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study

ABSTRACT Background Immune checkpoint inhibitor (ICI) monotherapy elicits limited intrahepatic responses in patients with advanced hepatocellular carcinoma (HCC). Here, we investigate the organ‐specific objective response rate (OSORR) of nivolumab plus ipilimumab (Nivo/Ipi) combination treatment, co...

Full description

Saved in:
Bibliographic Details
Main Authors: Jung Sun Kim, Youngun Kim, Beodeul Kang, Ilhwan Kim, Hyeyeong Kim, Won Suk Lee, Jung Yong Hong, Ho Yeong Lim, Han Sang Kim, Chang Gon Kim, Sanghoon Jung, Chansik An, Chan Kim, Hong Jae Chon
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:Cancer Medicine
Subjects:
advanced HCC
immune checkpoint inhibitor
Nivolumab monotherapy
Nivolumab plus ipilimumab
organ‐specific objective response rate
prior ICI treatment
Online Access:https://doi.org/10.1002/cam4.70997
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.70997

Similar Items